These signals trigger the ventricular contraction to be in coordination and improves the blood pumping as well. Often, pacemaker also contains an implantable cardioverter-defibrillator (ICD), which can deliver an electrical shock to reset the heartbeat, in situations where heart rhythm becomes extremely erratic. Cardiac resynchronization therapy also aids in reduction of symptoms of heart failure and lower your risk of heart failure and related complications, including death. Clinical studies also suggest that CRT decreases hospitalization and morbidity as well as improves in quality of life for the heart failure patients.
Companies covered:
- Medtronic PLC
- Abbott Laboratories
- Biotronik
- Boston Scientific Corporation
- Microport Scientific Corporation
- Medico S.P.A
- LivaNova PLC
- Cook Group Inc.
- Johnson & Johnson
- Lepu Medical Technology Co. Ltd.
Geographies covered:
- North America (U.S., Canada, Mexico)
- Europe (France, Germany, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, South Korea, Rest of Asia-Pacific)
- LAMEA (Brazil, South Arabia, South Africa, Rest of LAMEA)
Technological advancements and increasing awareness about benefits of CRT to boost market growth
Systolic heart failure is a major problem in U.S., with 550,000 new cases diagnosed and 287,000 deaths every year. Pharmacologic therapy has drastically improved outcomes in patients with heart failure, but hospitalizations from heart failure continue to increase the cost burden. Cardiac resynchronization therapy (CRT), introduced in the 1990s has been a revolution for many patients with persistent symptoms of systolic heart failure. The industry has been upgrading and innovating for providing better quality of life and higher survival chances for the patients. For instance, Medtronic announced FDA approval for their MR-Conditional CRT-Pacemakers.
Sedentary lifestyle and obesity expected to fuel growth
World Health Organization (WHO) in their report, mentioned the rate of obesity has tripled since 1975 worldwide. In 2016, over 1.9 billion adults belonging to age group 18 years or above were overweight and out of them, over one third of people were obese. These factors increase the risk of cardiovascular diseases significantly and eventually increase the chances of having a cardiac arrest. As a result, problems arising due to obesity would create growth pockets for cardiac resynchronization therapy market.
0 Comments